Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT05649384
Active, not recruiting Not applicable

Emergency Department Triage of Patients With Acute Chest Pain Based on the ESC 0/1-hour Algorithm (PRESC1SE-MI)

NCT05649384 · tracked via the Priya Life Science Spain tracker
Sponsor
University Hospital, Basel, Switzerland
Phase
Not applicable
Started
2020-12-01
Last updated
2026-09-17

Condition(s) studied

Acute Chest PainNSTEMI - Non-ST Segment Elevation MI

Investigational drug(s) / intervention(s)

European Society of Cardiology hs-cTnT/I 0 h/1 h algorithmEuropean Society of Cardiology hs-cTnT/I 0 h/3 h algorithm

European Society of Cardiology hs-cTnT/I 0 h/1 h algorithm: High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 1 hour later in the emergency department.

European Society of Cardiology hs-cTnT/I 0 h/3 h algorithm: High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 3 hours later in the emergency department.

Study summary

The PRESC1SE-MI study compares two algorithms for triage of patients presenting with chest pain and symptoms of heart attack (myocardial infarction) to the emergency department. Both algorithms are recommended by the European Society of Cardiology: the 0/3-hour algorithm and the 0/1-hour algorithm.

Currently, most emergency departments worldwide use the 0/3-hour troponin algorithm. Cardiac troponin (cTn) is a heart-specific biomarker which indicates damage of the heart muscle and which increases after a heart attack. In the 0/3-hour algorithm, the amount of troponin in the bloodstream is measured with a high-sensitivity assay at admission and 3 hours thereafter. Likewise, the 0/1-hour algorithm means that the blood sample in which the troponin is measured is collected at admission and 1 hour later. Since recent clinical studies suggest that the 0/1-hour algorithm is superior to the 0/3-hour algorithm, many hospitals consider switching to the 0/1-hour algorithm.

The aim of this study is to assess how feasible the time-saving 0/1-hour algorithm would be in reality and whether it provides the same accuracy and safety in the diagnosis of myocardial infarction as the current practice the 0/3-hour algorithm.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients aged 18 and above * Presentation with acute non-traumatic acute chest pain to the emergency department * Suspicion of acute myocardial infarction Exclusion Criteria: * Terminal kidney failure requiring dialysis * Cardiac arrest * Cardiogenic shock

Primary outcome measure(s)

Trial sites (20)

FacilityCityRegionStatus
Baylor St. Luke's Medical Center Houston Texas
St Andrew's War Memorial Hospital Brisbane Brisbane Australia
Vienna General Hospital (AKH Wien) Vienna Austria
University Central Hospital Helsinki Helsinki Finland
Attikon General Hospital Athens Athens Greece
Careggi University Hospital Florence Florence Italy
Azienda Ospedaliera San Giovanni Addolorata Roma Italy
Hospital Città della Salute e della Scienza di Torino Torino Italy
Emergency Institute for Cardiovascular Diseases C.C. Iliescu Bucharest Romania
Konkuk University Medical Center Seoul South Korea
Hospital Clinic Barcelona Barcelona Spain
University Hospital October 12 Madrid Madrid Spain
University Hospital Ramon y Cajal Madrid Spain
Hospital Clínico Universitario Valencia Valencia Spain
Kantonsspital Aarau Aarau Switzerland
St. Claraspital Basel Switzerland
Kantonsspital Luzern Lucerne Switzerland
University Hospital Zurich Zurich Switzerland
Royal London Hospital London United Kingdom
Royal Cornwall Hospitals Treliske Truro United Kingdom

More University Hospital, Basel, Switzerland trials in Spain

Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation Recruiting
The OPBC-07/microNAC Study Active, not recruiting
EnDovascular Therapy Plus Best Medical Treatment (BMT) Versus BMT Alone for MedIum VeSsel Occlusion sTroke Active, not recruiting
BAsel Syncope EvaLuation (BASEL IX) Study Active, not recruiting
The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema Recruiting

Other trials for the same condition

Advanced NanoTherapies Dual-API DCB to Treat De-Novo and ISR Lesions in Patients With Symptomatic Coronary Artery Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05649384 on ClinicalTrials.gov ↗ ← All trials in Spain